# Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

> **NCT06170710** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 173 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Anti-PD-1 monoclonal antibody
- **OTHER:** Postoperative CCRT

## Key facts

- **NCT ID:** NCT06170710
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2025-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 173 (ESTIMATED)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06170710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06170710, "Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06170710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*